Tragedy in Madhya Pradesh: Owner of Pharma Firm Arrested After 21 Children Die Linked to “Poisonous” Coldrif Cough Syrup

The Core of the Scandal

• Coldrif syrup (Batch SR-13, manufactured May 2025, expiring April 2027) was found to be “Not of Standard Quality” and adulterated. Laboratory tests revealed 48.6% diethylene glycol, a poisonous chemical more commonly used in antifreeze, capable of causing acute kidney failure and death.

• The syrup was distributed in several parts of Madhya Pradesh; numerous children (mostly under 5) developed sudden kidney problems after being treated for mild fever or cough. 

  Arrest & Regulatory Response

  • Ranganathan was taken into custody from his residence in Kodambakkam, Chennai, and is to be transported to Chhindwara, MP, where most deaths occurred. 

  • His manufacturing unit in Sunguvarchatram, Kancheepuram, has been sealed. His offices and equipment are being inspected, and all stocks of Coldrif and other Sresan products have been banned and seized.

  • Legal charges include culpable homicide not amounting to murder, drug adulteration, and violations under the Drugs & Cosmetics Act. Background & Legacy

  • Ranganathan has long been known in the industry—best known for Pronit, a nutritional syrup marketed heavily in southern India.

  • His manufacturing unit had been under scrutiny for years; reports suggest the facility was in poor condition, with rusting, leaking equipment, and lax safety compliance. 

  Wider Implications & Questions

  This tragedy raises serious questions about pharmaceutical regulation, quality control, and accountability:

  1. How did such a contaminated batch leave the factory undetected?
     Lapses in internal QC, weak oversight, or corruption could be factors.

  2. Are drug regulators and inspection systems strong enough?
     The incident suggests critical gaps in surveillance, audits, and enforcement.

  3. Who bears responsibility — the company, regulators, distributors, or doctors?
     Legal cases will need to untangle the chain of liability.

  4. What safeguards now?
     There must be stricter lab testing protocols, more frequent inspections, public disclosures of QC results, and fast action when red flags arise.

  Conclusion

  The Coldrif scandal is devastating, not just for the tragic loss of young lives, but as a stark reminder of how the pharmaceutical industry’s lapses can turn fatal. With the arrest of the owner and a full-scale probe underway, India’s drug safety regime faces a reckoning. For justice, prevention, and restoration of trust, systemic change is indispensable.